Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,011,800 | 1,920,700 | 2,602,000 | 2,730,000 | 2,152,300 |
| Marketable Securities | 7,784,700 | 7,888,300 | 7,917,500 | 8,114,800 | 7,761,300 |
| Receivables | 6,107,100 | 5,717,100 | 5,222,200 | 5,667,300 | 5,584,500 |
| Inventories | 3,018,000 | 2,873,600 | 2,714,900 | 2,580,500 | 2,562,000 |
| TOTAL | $19,333,600 | $19,081,600 | $18,871,500 | $19,479,200 | $18,634,800 |
| Non-Current Assets | |||||
| PPE Net | 4,439,200 | 4,305,900 | 4,225,500 | 4,146,400 | 4,006,100 |
| Investments And Advances | 8,490,900 | 7,722,400 | 6,978,800 | 5,396,500 | 5,778,500 |
| Intangibles | 1,120,100 | 1,102,200 | 1,058,700 | 1,038,600 | 1,017,200 |
| Other Non-Current Assets | 4,058,100 | 3,874,700 | 3,235,100 | 3,019,500 | 2,726,700 |
| TOTAL | $18,108,300 | $17,005,200 | $15,498,100 | $13,601,000 | $13,528,500 |
| Total Assets | $37,441,900 | $36,086,800 | $34,369,600 | $33,080,200 | $32,163,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 497,300 | 561,700 | 671,300 | 606,600 | 536,600 |
| Accrued Expenses | N/A | 2,360,900 | 2,392,900 | N/A | N/A |
| Other current liabilities | 2,536,500 | N/A | N/A | 2,357,900 | 2,644,700 |
| TOTAL | $3,661,000 | $3,508,600 | $3,580,900 | $3,423,400 | $3,598,600 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,984,000 | 1,983,600 | 1,983,300 | 1,982,900 | 1,982,600 |
| Deferred Revenues | 627,200 | 586,000 | 516,700 | 458,900 | 417,300 |
| aiOther Non-Current Liabilities | 1,543,600 | 1,463,200 | 908,500 | 854,100 | 832,400 |
| TOTAL | $4,455,000 | $4,372,400 | $3,797,600 | $3,683,700 | $3,660,300 |
| Total Liabilities | $8,116,000 | $7,881,000 | $7,378,500 | $7,107,100 | $7,258,900 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,890 | 110,235 | 110,186 | 109,762 | 108,947 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 30,755,200 | 29,414,600 | 27,982,300 | 27,260,300 | 26,100,700 |
| Other shareholders' equity | 59,800 | -69,800 | -76,900 | -81,300 | -176,900 |
| TOTAL | $29,325,900 | $28,205,800 | $26,991,100 | $25,973,100 | $24,904,400 |
| Total Liabilities And Equity | $37,441,900 | $36,086,800 | $34,369,600 | $33,080,200 | $32,163,300 |